Related Experiment Video

Updated: Mar 3, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?

Johannes Czernin1, Matthias Eiber2

  • 1Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California jczernin@mednet.ucla.edu.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|May 6, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.2K

Related Experiment Videos

Last Updated: Mar 3, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

Articles linked to this work by shared authors, journal, and citation graph.

Radiopharmaceutical Therapy-Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

PSMA PET Imaging for Prostate Cancer Recurrence After Minimally Invasive Focal Therapy: A Single-Center Retrospective Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Clinical Trial Protocol for LPS-Boost: Intensified [177Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Prognostic Value of PSMA PET-Derived Tumor Burden Stratification in Metastatic Hormone-Sensitive Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Optimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Renal Function Decline After 177Lu-PSMA-617 Versus Taxane-Based Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Propensity Score Analysis.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Serial Multitracer PET/CT for Characterization of the Inflammation-Fibrosis Axis in Liver Injury.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Association of ATM Alterations with Outcomes After 177Lu-PSMA-617 Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Glypican-3 as a Theranostic Target in Hepatocellular Carcinoma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Next-Generation Peptide Receptor Radionuclide Therapy: A Phase 1 Dose-Escalation and Dosimetry Study of 177Lu-DOTA-EB-TATE.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us